The Spectranetics Corporation

SPNC develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are sold in numerous countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads. The Company’s Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee, the AngioSculpt scoring balloon used in both peripheral and coronary procedures and Stellarex drug-coated balloon peripheral angioplasty platform. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets aspiration and cardiac laser catheters to treat blockages in the heart. The Lead Management (LM) product line includes excimer laser sheaths, dilator sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads.
Colorado Springs, US
Size (employees)
960 (est)+8%
The Spectranetics Corporation was founded in 1984 and is headquartered in Colorado Springs, US

The Spectranetics Corporation Office Locations

The Spectranetics Corporation has an office in Colorado Springs
Colorado Springs, US (HQ)
9965 Federal Dr
Show all (1)

The Spectranetics Corporation Financials and Metrics

The Spectranetics Corporation Financials

The Spectranetics Corporation's revenue was reported to be $270.8 m in FY, 2016

Revenue (Q2, 2017)

74.7 m

Gross profit (Q2, 2017)

56.2 m

Gross profit margin (Q2, 2017), %


Net income (Q2, 2017)

(24.6 m)

EBIT (Q2, 2017)

(21.3 m)

Market capitalization (09-Aug-2017)

1.7 b

Cash (30-Jun-2017)

57.5 m
The Spectranetics Corporation's current market capitalization is $1.7 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


158.8 m204.9 m246 m270.8 m

Revenue growth, %


Cost of goods sold

41.4 m51.4 m62.9 m68.3 m

Gross profit

117.5 m153.5 m183.1 m202.5 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


39.8 m39.6 m43.6 m58.8 m57.4 m61.7 m61.7 m62.9 m67.7 m68.3 m69.7 m74.7 m

Cost of goods sold

10.1 m10.3 m10.5 m14.7 m14.8 m15.9 m15.8 m16.1 m17 m16.9 m18.1 m18.5 m

Gross profit

29.7 m29.3 m33 m44.1 m42.6 m45.8 m45.9 m46.8 m50.8 m51.4 m51.6 m56.2 m

Gross profit Margin, %

USDFY, 2013FY, 2014FY, 2015FY, 2016


128.4 m95.5 m84.6 m57.2 m


2.7 m8.1 m8.1 m27.6 m

Current Assets

167.8 m172.3 m158.3 m135.5 m


28.3 m33.8 m44.7 m44.8 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


123.6 m120.9 m107 m103.5 m43.6 m49.3 m41.7 m67.5 m64.3 m58.9 m43.9 m57.5 m


10 m9.8 m26 m26.5 m27.7 m27.8 m27.5 m26.3 m25.7 m26.7 m28.9 m29.6 m

Current Assets

161.3 m162.3 m175.7 m174.6 m121.5 m125.8 m117.2 m144 m139.2 m133.6 m123.3 m142.3 m


26.6 m28.7 m30.5 m32.4 m38.3 m42.6 m45.1 m44.8 m44.6 m44.9 m45.5 m46.3 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(370 k)(40.9 m)(59.5 m)(58.1 m)

Depreciation and Amortization

10.6 m16.8 m26.6 m27.4 m

Accounts Receivable

(2.7 m)(2.7 m)(398 k)


(359 k)497 k497 k(3.7 m)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

434 k(5.7 m)(6.6 m)(13.9 m)(27.3 m)(7.2 m)(14.5 m)(17.3 m)(14.9 m)(13.3 m)(18.5 m)

Accounts Payable

4.6 m4.4 m4 m7.6 m9.5 m4.4 m5.3 m5.8 m6.6 m
Y, 2017

Financial Leverage

10.5 x
Show all financial metrics

The Spectranetics Corporation Market Value History

The Spectranetics Corporation's Web-traffic and Trends

The Spectranetics Corporation Company Life and Culture

You may also be interested in